MC2 Therapeutics A/S
MC2 Therapeutics A/S, headquartered in Denmark, is a pioneering biopharmaceutical company focused on developing innovative therapies for dermatological conditions. Founded in 2015, the company has rapidly established itself in the industry, particularly in the field of topical treatments that leverage its proprietary drug delivery technology. With a commitment to enhancing patient outcomes, MC2 Therapeutics offers unique products designed to improve the efficacy and tolerability of existing therapies. Their flagship offerings include advanced formulations that address unmet medical needs in skin health, setting them apart in a competitive market. Recognised for its scientific excellence, MC2 Therapeutics has achieved significant milestones, including successful clinical trials and partnerships that bolster its position as a leader in dermatology. The company continues to expand its operational reach, aiming to transform the landscape of skin treatment through innovation and patient-centric solutions.
DitchCarbon Score
How does MC2 Therapeutics A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MC2 Therapeutics A/S's score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
MC2 Therapeutics A/S's reported carbon emissions
MC2 Therapeutics A/S, headquartered in Denmark (DK), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that MC2 Therapeutics A/S may still be in the early stages of developing its climate commitments or reporting frameworks. As the company operates within the pharmaceutical industry, it is essential for them to consider establishing robust sustainability practices and emissions reduction strategies in line with industry standards. This could include setting science-based targets and participating in initiatives such as the Science Based Targets initiative (SBTi) to enhance their climate accountability and transparency in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
MC2 Therapeutics A/S is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
